drugset / Trial / NCT00924950

Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis

NCT00924950 ↗

Phase 4 Terminated 35 enrolled University of California, San Francisco
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether using Taclonex ointment under a hydrogel patch is more effective than using the ointment alone in treating psoriasis. Taclonex ointment is currently FDA approved for use on psoriasis. The hydrogel patch is a type of adhesive pad and contains no medications. It is currently FDA approved and has been shown to be safe and virtually free of side effects. The hypothesis is that psoriatic plaques which are treated with Taclonex ointment under a hydrogel patch will be more effectively treated compared to psoriatic plaques treated with Taclonex alone.

Timeline

Start
2009-06
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Taclonex Unknown — Topical

Indications